Arbutus Biopharma (NASDAQ:ABUS) Stock Rating Lowered by StockNews.com

Arbutus Biopharma (NASDAQ:ABUS) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

Other equities analysts also recently issued research reports about the stock. Chardan Capital reiterated a “buy” rating and issued a $5.00 target price (up previously from $4.50) on shares of Arbutus Biopharma in a research note on Wednesday, November 20th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a report on Tuesday, January 21st. Finally, JMP Securities lifted their price objective on shares of Arbutus Biopharma to $5.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, Arbutus Biopharma presently has an average rating of “Moderate Buy” and an average target price of $5.50.

Arbutus Biopharma Stock Down 0.4 %

ABUS opened at $3.44 on Tuesday. The company’s 50-day moving average price is $3.31 and its two-hundred day moving average price is $3.66. Arbutus Biopharma has a twelve month low of $2.30 and a twelve month high of $4.72. The stock has a market cap of $650.90 million, a price-to-earnings ratio of -7.99 and a beta of 1.78.

Institutional Investors Weigh In On Arbutus Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of ABUS. Two Seas Capital LP boosted its holdings in shares of Arbutus Biopharma by 4.2% during the fourth quarter. Two Seas Capital LP now owns 8,740,956 shares of the biopharmaceutical company’s stock worth $28,583,000 after purchasing an additional 353,568 shares during the period. Whitefort Capital Management LP boosted its position in shares of Arbutus Biopharma by 2.9% in the 4th quarter. Whitefort Capital Management LP now owns 13,241,916 shares of the biopharmaceutical company’s stock worth $43,301,000 after purchasing an additional 373,949 shares in the last quarter. Woodline Partners LP grew its stake in shares of Arbutus Biopharma by 45.4% in the fourth quarter. Woodline Partners LP now owns 971,628 shares of the biopharmaceutical company’s stock worth $3,177,000 after acquiring an additional 303,475 shares during the last quarter. Saba Capital Management L.P. grew its position in Arbutus Biopharma by 31.3% during the 4th quarter. Saba Capital Management L.P. now owns 887,993 shares of the biopharmaceutical company’s stock valued at $2,904,000 after purchasing an additional 211,566 shares during the last quarter. Finally, Rafferty Asset Management LLC grew its holdings in shares of Arbutus Biopharma by 27.6% during the fourth quarter. Rafferty Asset Management LLC now owns 146,803 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 31,782 shares during the last quarter. Institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.